PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25725289-12 2015 This signaling pathway represents a feedback loop whereby adenosine receptor signaling can lead to increased adenosine reuptake into cells via hENT1. Adenosine 58-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-148 26070128-4 2015 By reducing the uptake of extracellular adenosine, ENT1 inhibitors potentiate the cardioprotective effect of endogenous adenosine. Adenosine 40-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 26070128-4 2015 By reducing the uptake of extracellular adenosine, ENT1 inhibitors potentiate the cardioprotective effect of endogenous adenosine. Adenosine 120-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Adenosine 148-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-46 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Adenosine 148-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 25351985-1 2015 Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-73 25351985-1 2015 Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 25351985-1 2015 Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 24119573-3 2013 Altered adenosine metabolism and uptake by the endothelium leads to increased NO synthesis which then turns-off the expression of genes coding for a family of nucleoside membrane transporters belonging to equilibrative nucleoside transporters, particularly isoforms 1 (hENT1) and 2 (hENT2). Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 269-274 24768873-2 2014 The effect is mediated by inhibition of the adenosine transporter ENT1 (type 1 equilibrative nucleoside transporter), which provides protection for adenosine from intracellular metabolism, thus increasing its concentration and biological activity, particularly at sites of ischemia and tissue injury where it is formed. Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-70 24163005-1 2014 The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. Adenosine 4-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 24163005-2 2014 ENT1 is well established to play a role in adenosinergic signaling in the cardiovascular system by modulating adenosine levels. Adenosine 43-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 24163005-5 2014 Inhibition or absence of ENT1 is known to be cardioprotective, suggesting that the interaction of ethanol with ENT1 may promote adenosinergic cardioprotective pathways in the cardiovasculature.Ethanol sensitivity of adenosine uptake is altered by pharmacological activation of PKA and PKC. Adenosine 128-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-115 24586402-2 2014 Type 1 equilibrative nucleoside transporter (ENT1) is responsible for the majority of adenosine transport across the plasma membrane and is ubiquitously expressed in both humans and mice. Adenosine 86-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-49 24122028-13 2013 Thus, ADO specifically inhibits FcepsilonRI-induced degranulation of hSMCs primarily by an intracellular mechanism that requires its influx via equilibrative nucleoside transporter 1 (ENT1). Adenosine 6-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 144-182 24122028-13 2013 Thus, ADO specifically inhibits FcepsilonRI-induced degranulation of hSMCs primarily by an intracellular mechanism that requires its influx via equilibrative nucleoside transporter 1 (ENT1). Adenosine 6-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-188 21678404-7 2012 ENT1-mediated adenosine uptake was also enhanced. Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 21266914-8 2012 It has been speculated that the increase in the activities of ENT-1 and CNT-2 may reduce the availability of adenosine to adenosine receptors, thereby weakening the vascular functions of adenosine. Adenosine 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-67 22409811-3 2012 In vitro studies showed that neuron-specific expression of human equilibrative nucleoside transporter 1 (hENT1) decreases extracellular adenosine levels and adenosine A1 receptor activity. Adenosine 136-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-103 22409811-3 2012 In vitro studies showed that neuron-specific expression of human equilibrative nucleoside transporter 1 (hENT1) decreases extracellular adenosine levels and adenosine A1 receptor activity. Adenosine 136-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-110 21266914-3 2012 In vascular smooth muscle cells, 95% of adenosine transport is mediated by ENT-1 and the rest by ENT-2. Adenosine 40-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 21266914-4 2012 In endothelial cells, 60%, 10%, and 30% of adenosine transport are mediated by ENT-1, ENT-2, and CNT-2, respectively. Adenosine 43-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-84 21266914-8 2012 It has been speculated that the increase in the activities of ENT-1 and CNT-2 may reduce the availability of adenosine to adenosine receptors, thereby weakening the vascular functions of adenosine. Adenosine 122-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-67 21054262-5 2010 Acute ethanol elevates extracellular adenosine levels by selectively inhibiting the type 1 equilibrative nucleoside transporter, ENT1. Adenosine 37-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 21395582-0 2011 Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenosine levels in physiological and hypoxic-ischemic conditions. Adenosine 86-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-58 21223299-3 2011 Interestingly, ethanol is known to increase adenosine levels by inhibiting an ethanol-sensitive adenosine transporter, equilibrative nucleoside transporter type 1 (ENT1). Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-162 21223299-3 2011 Interestingly, ethanol is known to increase adenosine levels by inhibiting an ethanol-sensitive adenosine transporter, equilibrative nucleoside transporter type 1 (ENT1). Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-168 21283641-2 2011 In cultured cell and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known to regulate ethanol sensitivity and preference. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 21283641-2 2011 In cultured cell and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known to regulate ethanol sensitivity and preference. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 21283641-4 2011 PRINCIPAL FINDINGS: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced extracellular adenosine levels. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 21283641-4 2011 PRINCIPAL FINDINGS: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced extracellular adenosine levels. Adenosine 248-257 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 21453390-0 2011 Neuronal ENT1 takes up synaptic adenosine even under hypoxia/ischemia. Adenosine 32-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-13 21515851-8 2011 Cells from GDM exhibited increased insulin receptor A isoform expression in addition to the reported NO-dependent inhibition of hENT1-adenosine transport and SLC29A1 reporter repression, and increased extracellular concentration of adenosine and NO synthase activity. Adenosine 134-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-133 20728214-1 2010 Extracellular adenosine removal is via human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) in the endothelium, thus regulating adenosine-induced revascularization and angiogenesis. Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 20728214-1 2010 Extracellular adenosine removal is via human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) in the endothelium, thus regulating adenosine-induced revascularization and angiogenesis. Adenosine 143-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 20728214-8 2010 hEPC-3d cells exhibit hENT1-like adenosine transport (NBTI-sensitive, Na(+)-independent), which is absent in hEPC-14d cells. Adenosine 33-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-27 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. Adenosine 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20113503-9 2010 Hypoxanthine and adenine appeared to enter erythrocytes mainly through the hFNT1 nucleobase transporter whereas adenosine entered predominantly through the hENT1 nucleoside transporter. Adenosine 112-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 19193655-9 2009 TGF-beta1 reduced hENT1-mediated adenosine transport, hENT1 protein abundance, hENT1 mRNA expression, and SLC29A1 gene promoter activity, but increased Sp1 binding to DNA. Adenosine 33-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 19193655-2 2009 hENT1-mediated adenosine transport and expression are reduced in gestational diabetes and hyperglycaemia, conditions associated with increased synthesis and release of nitric oxide (NO) and TGF-beta1 in this cell type. Adenosine 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 19193655-5 2009 Total and hENT1-mediated adenosine transport was measured in the absence or presence of TGF-beta1, NG-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor), S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor), and/or KT-5823 (protein kinase G inhibitor) in control cells and cells expressing a truncated form of TGF-beta1 receptor type II (TTbetaRII). Adenosine 25-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 18064606-1 2008 High D-glucose reduces human equilibrative nucleoside transporter 1 (hENT1)-mediated adenosine uptake involving endothelial nitric oxide synthase (eNOS), mitogen-activated protein (MAP) kinase kinases 1 and 2/MAP kinases p42/44 (MEK/ERKs), and protein kinase C (PKC) activation in human umbilical vein endothelium (HUVEC). Adenosine 85-94 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 18064606-3 2008 HUVEC incubation (24 h) with high D-glucose (25 mM) reduced hENT1-adenosine transport and pGL3-hENT1(-1114) construct SLC29A1 reporter activity compared with normal D-glucose (5 mM). Adenosine 66-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Adenosine 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Adenosine 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-115 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Adenosine 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 19222701-10 2009 Instead, hENT1 expression affects dynamic changes in endogenous adenosine levels, as revealed by altered behavioral responses to drugs that affect adenosine receptor signalling. Adenosine 64-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-14 18703227-2 2008 Human equilibrative nucleoside transporters 1 (hENT1) and hENT2 are crucial to maintain physiological plasma levels of adenosine, thus modulating its several biological effects through adenosine receptor activation. Adenosine 119-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 18703227-8 2008 hPMEC from pre-eclampsia exhibit increased total transport (hENT1+hENT2), and maximal velocity (Vmax) for hENT2- (2-fold), but reduced Vmax for hENT1-mediated adenosine transport (75%), with no changes in apparent Km. Adenosine 159-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 144-149 18064606-1 2008 High D-glucose reduces human equilibrative nucleoside transporter 1 (hENT1)-mediated adenosine uptake involving endothelial nitric oxide synthase (eNOS), mitogen-activated protein (MAP) kinase kinases 1 and 2/MAP kinases p42/44 (MEK/ERKs), and protein kinase C (PKC) activation in human umbilical vein endothelium (HUVEC). Adenosine 85-94 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 15557207-0 2005 Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Adenosine 102-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-77 17883419-5 2007 Adenosine ENT1 uptake was the predominant transporter in both PBL(C) (55%) and PBL(LN) (46%). Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-14 17167068-7 2007 However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. Adenosine 171-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-78 16873718-2 2006 Previous studies have implicated the equilibrative nucleoside transporter family member equilibrative nucleoside transporter-1 (ENT1) in the regulation of cardiac adenosine levels. Adenosine 163-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-126 16873718-2 2006 Previous studies have implicated the equilibrative nucleoside transporter family member equilibrative nucleoside transporter-1 (ENT1) in the regulation of cardiac adenosine levels. Adenosine 163-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-132 16688763-2 2006 Adenosine transport via human equilibrative nucleoside transporters 1 (hENT1) is reduced by NO by unknown mechanisms in HUVEC. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 16688763-3 2006 We examined whether gestational diabetes-reduced adenosine transport results from lower hENT1 gene (SLC29A1) expression. Adenosine 49-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 16688763-3 2006 We examined whether gestational diabetes-reduced adenosine transport results from lower hENT1 gene (SLC29A1) expression. Adenosine 49-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-107 15933265-2 2005 Human umbilical vein endothelium (HUVEC) function in an environment with 3% to 5% O2 and exhibit efficient adenosine membrane transport via human equilibrative nucleoside transporters 1 (hENT1). Adenosine 107-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-192 15933265-4 2005 Hypoxia (0 to 24 hours, 2% and 1% O2) reduced maximal hENT1-adenosine transport velocity (V(max)) and maximal nitrobenzylthionosine (NBMPR, a high-affinity hENT1 protein ligand) binding, but increased extracellular adenosine concentration. Adenosine 60-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 16924660-2 2006 Adenosine uptake via the human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) has been proposed as a mechanism regulating adenosine plasma concentration, and therefore its vascular effects in human umbilical veins. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 16924660-2 2006 Adenosine uptake via the human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) has been proposed as a mechanism regulating adenosine plasma concentration, and therefore its vascular effects in human umbilical veins. Adenosine 137-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 16924660-3 2006 Thus, altered expression and/or activity of hENT1 or hENT2 could lead to abnormal physiological plasma adenosine level. Adenosine 103-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 16688763-8 2006 Thus, reduced adenosine transport may result from downregulation of SLC29A1 expression by NO in HUVEC from gestational diabetes. Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-75 15963471-12 2005 From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-121 15933265-8 2005 Thus, hypoxia-increased extracellular adenosine may result from reduced hENT1-adenosine transport in HUVEC. Adenosine 38-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 15933265-8 2005 Thus, hypoxia-increased extracellular adenosine may result from reduced hENT1-adenosine transport in HUVEC. Adenosine 78-87 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 15695555-5 2005 Although RT-PCR demonstrated the presence of equilibrative nucleoside transporter-1 (ENT-1) and ENT-2 mRNA, functional studies revealed that adenosine transport in HASMCs was predominantly mediated by ENT-1 and inhibited by nitrobenzylmercaptopurine riboside (NBMPR, IC(50) = 0.69 +/- 0.05 nM). Adenosine 141-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 201-206 15695555-12 2005 Pathologically, the increase in ENT-1 activity in diabetes may affect the availability of adenosine in the vicinity of adenosine receptors and, thus, alter vascular functions in diabetes. Adenosine 90-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Adenosine 158-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15557207-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is an important modulator of the physiological action of adenosine. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 15557207-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is an important modulator of the physiological action of adenosine. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 46-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 46-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 241-246 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 210-219 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 210-219 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 241-246 15557207-10 2005 In contrast, Ser160 and Met89 of hENT1, respectively, play a dominant role in conferring sensitivity to dipyridamole and adenosine/guanosine affinity. Adenosine 121-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 15037197-2 2004 hENT1 is ubiquitously expressed and plays an important role in the disposition and pharmacological activity of nucleoside drugs and nucleosides, such as adenosine. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-10 2004 For example, this conversion reduces sensitivity of hENT1 to the inhibitors NBMPR, DP, and DZ and reduces its transport affinity for the natural nucleosides cytidine and adenosine. Adenosine 170-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenosine 157-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-34 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenosine 157-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-175 11909821-6 2002 Our findings demonstrate that inhibition of adenosine transport via hENT1 in endothelial cells cultured in 25 mmol/L D-glucose could be due to stimulation of P2Y2 purinoceptors by ATP, which is released from these cells in response to D-glucose. Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 12820662-4 2003 Uptake studies demonstrated that the majority of adenosine transport was mediated by hENT1, which was localized to both apical and basolateral membranes, with a smaller hENT2-mediated component in basolateral membranes. Adenosine 49-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-90 11814344-2 2002 hENT1 is involved in the uptake of natural nucleosides, including regulation of the physiological effects of extracellular adenosine, and transports nucleoside drugs used in the treatment of cancer and viral diseases. Adenosine 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 10722669-8 2000 7-, and 19.3-fold lower affinity than hENT1 for thymidine, adenosine, cytidine, and guanosine, respectively. Adenosine 59-68 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 11584005-0 2001 Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. Adenosine 144-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 11584005-1 2001 The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. Adenosine 218-227 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 11311901-6 2001 The apparent reciprocal distribution of hENT1 and hENT2 in human brain suggests that these nucleoside transporter proteins are produced in distinct regions of the CNS where they function in nucleoside salvage and/or regulation of exogenous adenosine. Adenosine 240-249 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Adenosine 24-33 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 35408815-6 2022 Dipyridamole significantly reduced cholesterol accumulation in fibroblasts and rescued mitochondrial deficits; the mechanism elicited by dipyridamole relies on activation of the adenosine A2AR subtype subsequent to the increased levels of extracellular adenosine due to the inhibition of ENT1. Adenosine 178-187 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 288-292 35408815-6 2022 Dipyridamole significantly reduced cholesterol accumulation in fibroblasts and rescued mitochondrial deficits; the mechanism elicited by dipyridamole relies on activation of the adenosine A2AR subtype subsequent to the increased levels of extracellular adenosine due to the inhibition of ENT1. Adenosine 253-262 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 288-292 33052430-3 2021 Extracellular adenosine level is controlled through the equilibrative nucleoside transporter 1 (ENT-1) and the enzyme adenosine deaminase (ADA). Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-94 33052430-3 2021 Extracellular adenosine level is controlled through the equilibrative nucleoside transporter 1 (ENT-1) and the enzyme adenosine deaminase (ADA). Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-101 33052430-4 2021 The aim of this study was to determine the control of adenosine blood level (ABL) via ENT-1 and ADA during apnoea-induced hypoxia in elite freedivers was similar to high-altitude adaptation. Adenosine 54-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 9705281-3 1998 When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. Adenosine 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Adenosine 94-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Adenosine 118-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Adenosine 265-274 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 35042768-0 2022 Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol. Adenosine 67-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 35042768-2 2022 A1Rs on other striatal neurons are activated by an adenosine tone that is limited by equilibrative nucleoside transporter 1 (ENT1) that is enriched on astrocytes and is ethanol-sensitive. Adenosine 51-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-123 35042768-2 2022 A1Rs on other striatal neurons are activated by an adenosine tone that is limited by equilibrative nucleoside transporter 1 (ENT1) that is enriched on astrocytes and is ethanol-sensitive. Adenosine 51-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 35042768-7 2022 By imaging the genetically encoded fluorescent adenosine sensor GRAB-Ado, we identified a striatal extracellular adenosine tone that was elevated by the ENT1 inhibitor and sensitive to gliotoxin fluorocitrate. Adenosine 47-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-157 35042768-7 2022 By imaging the genetically encoded fluorescent adenosine sensor GRAB-Ado, we identified a striatal extracellular adenosine tone that was elevated by the ENT1 inhibitor and sensitive to gliotoxin fluorocitrate. Adenosine 113-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-157 35042768-8 2022 Finally, we identified that ethanol (50 mM) promoted A1R-mediated inhibition of dopamine release, through diminishing adenosine uptake via ENT1. Adenosine 118-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 139-143 35042768-9 2022 Together, these data reveal that dopamine output dynamics are gated by a striatal adenosine tone, limiting amplitude but promoting contrast, regulated by ENT1, and promoted by ethanol. Adenosine 82-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-57 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 174-178 33324223-3 2020 Adenosine and the key adenosine regulators adenosine deaminase (ADA), adenosine kinase (ADK), and equilibrative nucleoside transporter 1 may play a role in COVID-19 pathogenesis. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 33324223-3 2020 Adenosine and the key adenosine regulators adenosine deaminase (ADA), adenosine kinase (ADK), and equilibrative nucleoside transporter 1 may play a role in COVID-19 pathogenesis. Adenosine 22-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 33324223-5 2020 Depending on the stage of exposure to and infection by SARS-CoV-2, enhancing adenosine levels by targeting key adenosine regulators such as ADA, ADK and equilibrative nucleoside transporter 1 might find therapeutic use against COVID-19 and warrants further investigation. Adenosine 77-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-191 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 32858046-7 2020 Effects of adenosine A2 receptors antagonists and ENT1/2 inhibitor were prevented by L-NAME, indicating that nitric oxide production inhibition prevents adenosine from increasing parasitic burden. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-56 32523687-2 2020 We have previously demonstrated that sustained adenosine exposure by inhibition of adenosine degradation impairs lung endothelial barrier integrity and causes intrinsic apoptosis through equilibrative nucleoside transporter1/2-mediated intracellular adenosine signaling. Adenosine 47-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-226 32824670-0 2020 Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells. Adenosine 103-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 32824670-0 2020 Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells. Adenosine 103-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-54 32824670-10 2020 In conclusion, the lower expression and activity of the ENT1 transporter in mesenchymal GSCs contributes to the high level of extracellular adenosine that these GSCs present. Adenosine 140-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. Adenosine 189-198 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-11 2020 Results demonstrated that ENT1 was more important than ENT2 or CNT3 in determining plasma adenosine concentrations, indicated modest roles of ENT1 in the homeostasis of other nucleosides, and suggested that none of the transporters is a major participant in handling of nucleobases. Adenosine 90-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 32523687-2 2020 We have previously demonstrated that sustained adenosine exposure by inhibition of adenosine degradation impairs lung endothelial barrier integrity and causes intrinsic apoptosis through equilibrative nucleoside transporter1/2-mediated intracellular adenosine signaling. Adenosine 83-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-226 32523687-2 2020 We have previously demonstrated that sustained adenosine exposure by inhibition of adenosine degradation impairs lung endothelial barrier integrity and causes intrinsic apoptosis through equilibrative nucleoside transporter1/2-mediated intracellular adenosine signaling. Adenosine 83-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-226 32523687-3 2020 In this study, we further demonstrated that sustained adenosine exposure increased mitochondrial reactive oxygen species and reduced mitochondrial respiration via equilibrative nucleoside transporter1/2, but not via adenosine receptor-mediated signaling. Adenosine 54-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 163-202 32523687-8 2020 Our results suggest that inhibition of equilibrative nucleoside transporter1/2 and mitochondria-targeted antioxidants may be potential therapeutic approaches for lung diseases associated with sustained elevated adenosine. Adenosine 211-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-78 31551431-4 2019 For this study, a prototypical SLC/GPCR pair was selected, i.e. the equilibrative nucleoside transporter-1 (SLC29A1/ENT1) and an adenosine receptor (AR), for which adenosine is the substrate/ligand. Adenosine 164-173 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-115 31721163-0 2020 beta3 adrenoceptor-induced cholinergic bladder inhibition involves EPAC1 and PKC favoring ENT1-mediated adenosine outflow from the human and rat detrusor. Adenosine 104-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-94 32141895-10 2020 Follow-up studies showed that erythrocyte equilibrative nucleoside transporter 1 (eENT1) is a key purinergic cellular component controlling plasma adenosine in humans at high altitude and mice under hypoxia and underlies the quicker and higher elevation of plasma adenosine upon re-ascent because of prior hypoxia-induced degradation of eENT1. Adenosine 147-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 32141895-10 2020 Follow-up studies showed that erythrocyte equilibrative nucleoside transporter 1 (eENT1) is a key purinergic cellular component controlling plasma adenosine in humans at high altitude and mice under hypoxia and underlies the quicker and higher elevation of plasma adenosine upon re-ascent because of prior hypoxia-induced degradation of eENT1. Adenosine 264-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 18-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 18-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 162-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 162-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 29680437-2 2018 We hypothesized that an increase in extracellular adenosine induced by inhibitors of adenosine transporters, such as the non-selective ENT1/ENT2 inhibitor dipyridamole, would result in an improvement in RLS symptoms. Adenosine 50-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 135-139 29851527-3 2019 Ticagrelor"s pleiotropic effects on reuptake of adenosine via inhibition of equilibrative nucleoside transporter 1 (ENT1) have been hypothesized to contribute to this. Adenosine 48-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-114 29851527-3 2019 Ticagrelor"s pleiotropic effects on reuptake of adenosine via inhibition of equilibrative nucleoside transporter 1 (ENT1) have been hypothesized to contribute to this. Adenosine 48-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-120 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Adenosine 72-81 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-34 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Adenosine 264-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-34 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Adenosine 264-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 216-223 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Adenosine 111-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Adenosine 111-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 31235912-3 2019 Despite its importance in human physiology and pharmacology, the molecular basis of hENT1-mediated adenosine transport and its inhibition by AdoRIs are limited, owing to the absence of structural information on hENT1. Adenosine 99-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 31235912-5 2019 Combined with mutagenesis study, our structural analyses elucidate two distinct inhibitory mechanisms exhibited on hENT1 and provide insight into adenosine recognition and transport. Adenosine 146-155 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-120 31235912-6 2019 Our studies provide a platform for improved pharmacological intervention of adenosine and nucleoside analog drug transport by hENT1. Adenosine 76-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 126-131 29483661-8 2018 In pyramidal neurons, changes in ENT1 and ADA mRNA may suggest increased catabolism of adenosine. Adenosine 87-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-37 27995448-5 2017 hENT1 transports the substrate adenosine with a Km of 215 +- 34 micromol/L and a Vmax of 578 +- 23.4 nmol mg-1 min-1. Adenosine 31-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-7 2017 Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. Adenosine 20-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 11-16 28292464-1 2017 INTRODUCTION: Adenosine is taken up via human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) at a physiological extracellular pH (pHo ~7.4) in human umbilical vein endothelial cells (HUVECs). Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-92 28292464-7 2017 RESULTS: Overall adenosine transport (i.e., hENT1+hENT2) was semisaturable and partially inhibited by 1 mumol/L, but abolished by 10 mumol/L NBTI in cells non-treated or treated with NH4Cl. Adenosine 17-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28041785-2 2017 The equilibrative nucleoside transporter 1 (ENT1) terminates the action of adenosine by removal from the extracellular environment. Adenosine 75-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-42 28041785-2 2017 The equilibrative nucleoside transporter 1 (ENT1) terminates the action of adenosine by removal from the extracellular environment. Adenosine 75-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 28041785-3 2017 Therefore, it is proposed that inhibition of ENT1 in respiratory disease patients leads to increased adenosine concentrations, triggering bronchospasm and dyspnoea. Adenosine 101-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-49 26156883-9 2015 Ticagrelor is a more potent P2Y12 inhibitor than clopidogrel and also inhibits cellular adenosine uptake via equilibrative nucleoside transporter (ENT) 1, whereas clopidogrel does not. Adenosine 88-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-153 25869606-7 2015 hENT1-adenosine maximal transport activity was reduced (P=0.041), but the expression was increased (P=0.001) in HUVECs from this group. Adenosine 6-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 25869606-8 2015 CPZ increased hENT1-adenosine transport (P=0.040) and hENT1 plasma membrane accumulation only in cells from pGWG. Adenosine 20-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 27694321-4 2016 This additional effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors. Adenosine 221-230 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 160-164